BCL2L1 and prostate carcinoma: Adipose MSC‐derived exosomes were suggested to inhibit prostate cancer via delivery of miR‐145 by reducing the activity of Bcl‐xL and promoting apoptosis through the caspase‐3/7 pathway.15